MDR summary reporting expansion planned by FDA; program begins with about 30 firms.
This article was originally published in The Gray Sheet
SUMMARY MDR REPORTING PROGRAM TO BEGIN WITH 30 MANUFACTURERS that responded to FDA's request for participants mailed out July 31. Under the reporting schedule outlined in the agency's letter to firms, the first quarterly reports will be due in Jan. 31, 1998. FDA is in the process of sending letters of acceptance to the 30 companies participating in summary reporting. The letters note that the firms are exempt from regular MDR reporting requirements for events covered by summary reporting. FDA has identified types of events for the devices that qualify for summary reporting. Manufacturers also can propose additional types of events, but they would have to be reviewed by FDA.
You may also be interested in...
FDA Quietly Sunsetting Summary Reporting Program For Adverse Events, Readies Public Release Of Millions Of Pre-2017 Summarized MDR Reports
The US FDA expects to turn the lights out on its 22-year-old Alternative Summary Reporting Program for adverse events at the end of May, the agency tells Medtech Insight. But it's the FDA's upcoming online release of millions of summarized Medical Device Reports sent to the agency between 1998 and 2017 that could have the tongues of industry – and the public – wagging.
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.